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Background: Human amniotic fluid stem (hAFS) cells have become an attractive stem cell source for medical
therapy due to both their ability to propagate as stem cells and the lack of ethical debate that comes with the use
of embryonic stem cells. Although techniques to derive stem cells from amniotic fluid are available, the techniques
have limitations for clinical uses, including a requirement of long periods of time for stem cell production,
population heterogeneity and xeno-contamination from using animal antibody-coated magnetic beads. Herein we
describe a novel isolation method that fits for hAFS derivation for cell-based therapy.
Methods and Results: With our method, single hAFS cells generate colonies in a primary culture of amniotic fluid
cells. Individual hAFS colonies are then expanded by subculturing in order to make a clonal hAFS cell line. This
method allows derivation of a substantial amount of a pure stem cell population within a short period of time.
Indeed, 10
8 cells from a clonal hAFS line can be derived in two weeks using our method, while previous
techniques require two months. The resultant hAFS cells show a 2-5 times greater proliferative ability than with
previous techniques and a population doubling time of 0.8 days. The hAFS cells exhibit typical hAFS cell
characteristics including the ability to differentiate into adipogenic-, osteogenic- and neurogenic lineages,
expression of specific stem cell markers including Oct4, SSEA4, CD29, CD44, CD73, CD90, CD105 and CD133, and
maintenance of a normal karyotype over long culture periods.
Conclusions: We have created a novel hAFS cell derivation method that can produce a vast amount of high
quality stem cells within a short period of time. Our technique makes possibility for providing autogenic fetal stem
cells and allogeneic cells for future cell-based therapy.
Background
With the hope of using stem cells for medical therapy,
research and understanding of many aspects of stem cell
biology has increased extensively. Stem cells from many
sources have been explored for their advantages and
limitations in clinical use. There are significant limita-
tions in the use of adult tissue stem cells and embryonic
stem cells. Specifically, for adult tissue stem cells, only a
small amount of stem cells are able to be obtained, and
these cannot be effectively propagated. The use of
embryonic stem cells (ESC) is hindered by ethical con-
cerns, feeder cell requirements and teratoma formation.
Thus, a new source of human stem cells for use in clini-
cal purposes is needed.
Amniotic fluid (AF) cells are the heterogeneous cell
population of exfoliated fetal and amniotic cells [1],
which are routinely harvested by amniocentesis for fetal
genetic determination in prenatal diagnosis. In 2003,
Prusa et al. [2] reported the discovery of OCT-4 positive
cells in amniotic fluid, which is a pluri-potent character-
istics. The biology of human amniotic fluid stem (hAFS)
cells was subsequently explored in several reports
[1,3-6]. The potency of hAFS cells seems to be between
pluripotent ESC and adult stem cells, the cells express
some pluri-potent stem cell markers. The hAFS cells
can grow in a simple culture without a feeder cell
requirement. They have high in vitro proliferation
potential (over 250 population doublings with a dou-
bling time of 1.6 days). Moreover, hAFS cells are not
* Correspondence: sitsu@mahidol.ac.th
1Stem Cell Research and Development Unit, Department of Obstetrics &
Gynecology, Faculty of Medicine Siriraj Hospital, Mahidol University, Bangkok,
10700, Thailand
Full list of author information is available at the end of the article
Phermthai et al. BMC Cell Biology 2010, 11:79
http://www.biomedcentral.com/1471-2121/11/79
© 2010 Phermthai et al; licensee BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative
Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
reproduction in any medium, provided the original work is properly cited.subject to teratocarcinoma formation and ethical
debates [1,2,5]. These characteristics make hAFS cells
an attractive source for providing a variety of major his-
tocompatibility complex immunity. Their broad spec-
trum ability of lineage differentiation and specialized
function has been reported in all three germ layers [3,5].
Thus, AF is an appropriate source of stem cells for clini-
cal purposes.
The first technique to derive hAFS cells was developed
in 2004 by Tsai et al. [1], who reported a two-stage cul-
ture technique. With the protocol, non-adherent cells
from routine amniocentesis were used for hAFS cell
derivation, but the yield showed heterogeneity within
the hAFS cell population. In 2006, Tsai et al. [3] estab-
lished an optional protocol following the two-stage cul-
ture method for generating high population purity by
constructing a clonal hAFS cell line from a single hAFS
cell. Subsequently, Kim et al. (2007) [4] presented a pro-
tocol for deriving hAFS cells. The technique is per-
formed by prolonging an in vitro hAFS cell culture with
subsequent subculturing until a stem cell population
with a homogeneous morphology can be obtained. In
2007, De Coppi et al. [5] demonstrated a hAFS cell iso-
lation protocol based on the principle of immunoselec-
tion. This method specifically selected the c-Kit positive
stem cells from amniotic fluid using magnetic cell sort-
ing and was followed by clonal cell culture. This immu-
noselection technique is efficient for producing a high
purity hAFS cell population, but the process utilizes
xeno-antibodies and micromagnetic beads.
Although several hAFS cell derivation techniques have
now been developed, the existing techniques are unsui-
table for hAFS production for medical purposes because
these methods often result in contamination with other
cell types or contamination with antibodies raised from
animals. Additionally, these techniques require a long
period of time for stem cell production. Hence, a better
method which allows utilization of these cells for cell-
based therapy needs to be developed.
In the current study, we present the starter cell
method as an efficient technique that is suitable to
derive hAFS cells for therapeutic purposes.
Methods
Derivation of hAFS cells with the starter cell method
Five milliliters of fifteen independent amniotic fluid
samples were obtained from 16-20 week pregnant
women who underwent amniocentesis for fetal genetic
determination in routine prenatal diagnosis. The study
protocol was approved by the Ethics Committee of Sir-
iraj hospital, Mahidol University, Thailand and each par-
ticipant received an informed consent document. Cells
were immediately isolated from amniotic fluid and cell
debris by centrifugation at 2,100 rpm for 5 min. The
pellet cells were resuspended with 5 ml of Chang med-
ium (Irvine Scientific, CA, USA), which has been used
in routine amniocentesis culture. A resuspension was
plated on a 100 mm
2 tissue culture dish (Nunc, NY)
and incubated at 37°C in humidified 5% CO2,5 %O 2 for
3-4 days. To identify the starter cells, the distinct fibro-
blast-like cells in the primary culture dish were observed
under inverted microscope. The individual single hAFS
cells were cultured continuously as starter cells to form
hAFS cell colonies. To keep each colony at the proper
distance, only one starter cell was allowed to exist under
a microscopic field using 10× magnifications. Unneeded
starter cells were mechanical removed by pipette tip.
For a colony forming from a starter cell, only the starter
cell was continued in culture. The medium and non-
adherent cells were removed from the primary culture
dish. Five milliliters of hAFS cell medium containing
a-MEM medium (Gibco, Invitrogen, CA) supplemented
with 15% ES-FBS (PAA, Pasching, Austria), 1% gluta-
mine (Sigma, MO), 1% penicillin/streptomycin (Bio-
chrom, Berlin, Germany), 18% Chang B and 2% Chang
C (Irvine Scientific, CA) and 10 ng/ml bFGF (Chemicon,
Millipore, MA) was added to the culture dish. The cul-
ture was maintained in the primary culture dish for
48 h. The cells in each colony were counted in order to
predict and select a clone for hAFS cell expansion.
Next, each hAFS cell colony was mechanically picked
up under inverted microscope using fine-tipped pipettes.
The cells in each hAFS cell colony were re-seeded into
a well of a 24-well plate. The culture was performed at
37°C under humidified 5% CO2,5 %O 2.W h e nac l o n a l
hAFS reached confluence at 70% of the culturing area,
subculturing was performed by trypsinization and re-
plating into a 25 cm
2 tissue culture flask. The medium
was changed every other day. The hAFS cells were
allowed to expand to 70% confluence and then routinely
subcultured with a dilution of 1:3.
Immunofluorescent staining of hAFS cells
hAFS cell markers were characterized using fluorescence
microscope detection and flow cytometry analysis.
For immunofluorescence, hAFS cells at 70% confluence
were fixed with 4% paraformaldehyde (Merck,
Darmstadt, Germany). Cells were stained overnight with
primary antibody against Oct-4a (Santa Cruz Biotech-
nology, CA) and SSEA-4 (Chemicon, Millipore, MA).
The cells were then washed twice with PBS-Tween (PBS
+0.5% Tween-20; UBS, OH) before staining with a 1:200
dilution of rabbit anti-human IgG secondary antibody
(Chemicon, Millipore, MA). The specificity of each reac-
tion was visualized by inverted fluorescent microscopy.
For flow cytometry analysis, hAFS cells were harvested
and stained with FITC or PE-conjugated antibodies
against CD29, CD44, CD90, CD105, CD133 (E-
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Dickinson, NJ) and Oct-4a. The cells were fixed with 1%
paraformaldehyde. The analysis was performed using a
Beckton Dickinson flow cytometer (Beckton Dickinson,
NJ).
Reverse-transciptase PCR
T o t a lR N Aw a se x t r a c t e df r o mh A F Sc e l l sb yP h e n o l -
Chloroform and used as a template for reverse tran-
scription. The cDNA was made by using RevertAid First
Strand cDNA Synthesis Kit (Fermentas, EU). The pri-
mers used in PCR are as follows:
Oct-4 (247 bp) sense, 5′-CGTGAAGCTGGAGAAG-
GAGAAGCTG-3′, and antisense, 5′-CAAGGGCCG-
CAGCTTACACATGTTC-3′;
HLA-ABC (394 bp) sense, 5′-GTATTTCTTCA-
CATCCGTGTCCCG-3′,a n da n t i s e n s e ,5 ′-GTCCGCC
GCGGTCCAAGAGCGCAG-3′;
HLA-DR (220 bp) sense, 5′-CTGATGAGCGCTCAG-
GAATCATGG-3′, and antisense, 5′-GACTTACTT-
CAGTTTGTGGTGAGGGAAG-3′;
Nestin (395 bp) sense, 5′-CCAGAAACTCAAGCAC-
CAC-3′, and antisense, 5′-TTTTCCACTCCAGC-
CATCC-3′;
Nanog (161 bp) sense, 5′-AGTCCCAAAGGCAAA-
CAACCCACTTC-3′, and antisense, 5′-
TGCTGGAGGCTGAGGTATTTCTGTCTC-3′;
Sox2 (449 bp) sense, 5′-CCCCCGGCGGCAATAGCA-
3′, and antisense, 5′-TCGGCGCCGGGAGATACAT-3′;
and beta-Actin (107 bp) sense, 5′-ATGTGGCCGAG-
GACTTTGATT-3′, and antisense, 5′-AGTGGGGTGG
CTTTTAGGATG-3′.
The cDNA amplification for Oct-4 and HLA-ABC
were performed by the following PCR conditions: initial
denaturing at 95°C for 5 min and 35 cycles of 94°C for
45 sec, 57°C for 1 min, 70°C for 1 min and extension at
70°C for 10 min. For HLA-DR, Nestin, Nanog, Sox2 and
b-actin, the PCR conditions were as follows: 95°C for 5
min and 35 cycles of 94°C for 45 sec, 52°C for 1 min,
70°C for 1 min and extension at 70°C for 10 min.
Differentiation
To investigate the differentiation capacity, hAFS cells
were in vitro differentiated into three different cell spe-
cific lineages, including adipogenic, osteogenic and neu-
rogenic lineages. This hAFS cells were cultured in hAFS
medium until 70% confluence and then shifted to a spe-
cific induction medium under the same condition of 5%
CO2,5 %O 2 at 37°C. The medium was changed twice a
week. For differentiation to osteogenic and adipogenic
lineages, the obtained cells were cultured in the appro-
priate medium. The osteogenic medium contains alpha-
MEM (Gibco) supplemented with 10% ES-FBS (PAA),
0.1 μM dexamethasone (Sigma), 10 mM glycerol-2-
phosphate (Sigma) and 50 μM ascorbic acid (Sigma).
The adipogenic medium contains alpha-MEM (Gibco)
supplemented with 10% ES-FBS (PAA), 1 μM dexa-
methasone (Sigma), 5 μg/ml insulin (Sigma), 0.5 mM
3-isobutyl-1-methylxanthine (Sigma), and 60 μMi n d o -
methacin (Sigma). For neural differentiation, hAFS cells
were cultured in neurogenic inducing medium contain-
ing alpha-MEM (Gibco) supplemented with 20% ES-FBS
(PAA), 1 μM beta-mercaptoethanol (Sigma), and 5 ng/
ml basic FGF (Invitrogen) for 24 h and then shifted
to serum-depleted medium (alpha-MEM, 10 uM beta-
mercaptoethanol) for 5 h.
Immunochemical staining of differentiated cells
The osteogenesis was assessed by alkaline phosphatase
enzyme activity. Calcium accumulation was examined
using von Kossa staining. The Oil Red O staining was
used for detection of intracellular lipid droplet forma-
tion for evaluating adipogenesis. For evaluation of neural
differentiation, the neuron specific class III b-tubulin
(TuJ-1) was used.
Results
Almost all samples (14 out of 15) showed success for
derivation of clonal hAFS cell lines. At day 3 of primary
culture of the independent hAF samples, we found four
to eight single hAFS cells adhering in a distinct area of
the culture dish. A hAFS cell in fibroblastic cell type is
shown in Figures 1A and 1B. Each single cell was used
for hAFS cell colony expansion, which we denoted as
the “starter cell”. After allowing growth in hAFS med-
ium for 48 h, each formed a colony. Each colony con-
tained about 100-300 cells (Figure 1B). The morphologic
characteristics of the hAFS cell colonies were as follows:
1) each cell within a colony stayed equidistant from
other cells within that same colony, 2) most cells in a
colony were in metaphase, and 3) cells in colonies
showed the morphology of fibroblast-like cells (Figure
1C). An individual colony in primary culture was
expanded as a clonal hAFS cell line. Each independent
colony was removed and re-seeded into a 24-well cul-
ture plate as the first subculture passage (passage 1).
The clonal hAFS reached 70% confluence (about
30,000-35,000 cells) by 3-4 days after cell seeding. The
hAFS cells can be expanded up to 10
7 cells within a fol-
lowing week by subsequent culturing to passage 2 in a
25 cm
2 culture flask and then 75 cm
2 culture flasks.
Using our method, 10
10 cells from a clonal hAFS cell
population can be derived within weeks.
Notably, we found that the resultant hAFS cells have
the highest proliferation potential in primary culture
(passage 0), with a population doubling time of 0.3 days.
The proliferative ability was gradually reduced during
early subculture passages (from passage 0 to passage 4).
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were 0.5, 0.6 and 0.8 days, respectively. After passage 4,
hAFS cells showed a stable rate of cell proliferation with
a doubling time of about 0.8 days. A normal karyotype
of 46XX and 46XY was observed in clonal hAFS cells at
passage 18. The growth rate, population accumulation
and population doubling time of the resultant hAFS
cells are shown in Figures 2A and 2B. The hAFS cells
derived by our technique and two other previous techni-
ques were compared based on their accumulation num-
bers, and this data is presented in Figure 2C.
The selected starter cell is a fibroblast-like cell, which
was obtained from an adherent stem cell on day 3 of
the primary human amniotic fluid cell culture. We did
often find contamination with other cell types in the
human AF samples, such as epithelial cells, which can
form colonies. However, the morphological appearance
of these colonies is obviously different from the hAFS
cell colonies. Over 85% of the adherent single cells in
the primary culture dish at day 3 are hAFS cells, with
fibroblastic morphology. Eighty to one hundred percent
of single hAFS cells can be in vitro extended and form a
good quality clonal hAFS line.
The hAFS cells were evaluated for pluripotent charac-
teristic by expression of the Oct-4a transcription factor
by immunocytochemical examination and RT-PCR. The
clonal hAFS cell lines at passage 18 were used for these
studies. Immunofluorescence detection showed that
Figure 1 Derivation of clonal hAFS cell lines by the starter cell method. (A) and (B) A hAFS starter cell of fibroblastic type (arrow) was
found early after a routine amniocentesis culture, (C) the colony appearance of a clonal hAFS cell line at 48 h in the primary culture dish, (D)
morphology of hAFS cells derived by the starter cell method at subculture passage 3.
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4a (Figure 3A). Gene expression analysis revealed a PCR
product for Oct-4 with a size of 247 bp, but not Nanog
and Sox2 (Figure 3B). In addition, we analyzed hAFS
cells for expression of immunological factors, and analy-
sis yielded a PCR product for HLA-ABC with a product
size of 394 bp using RT-PCR; however, we did not
observe expression of HLA-DR (Figure 3B). More anti-
genic characteristics of hAFS cells were investigated by
flow cytometry analysis. The results demonstrated high
positive signals for mesenchymal stem cell markers
CD29, CD44, CD73, CD105, CD133 but low signals for
CD90. The hAFS cells show a negative signal for hema-
topoietic stem cell markers CD34 and CD45 on the
surface of hAFS cells (Figure 3C). For detection of pluri-
potent embryonic stem cell markers using flow cyt-
ometer, 24-41% of cells within the hAFS cell population
expressed OCT-4a, whereas 48-91% of the cell popula-
tion had a positive SSEA-4 signal. Homogeneity of the
obtained hAFS cell population was observed by flow
cytometry, in which 99-100% of cells within the popula-
tion expressed CD29, CD44, CD73 and CD105.
To evaluate the differentiation ability of clonal hAFS
cells derived by our method, the cells were in vitro
induced into adipocytes, osteoblasts and neurons by
lineage-specific induction mediums. For osteogenic dif-
ferentiation, the cells showed positive alkaline phospha-
tase staining after incubation in osteogenic induction
medium for 3 weeks (Figure 4A). The calcium minerali-
zation of hAFS-derived osteogenic cells was verified by a
photochemical reaction using von Kossa staining (Figure
4B). For adipogenic differentiation, the clonal hAFS cells
showed morphologic changes at day 6 under adipogenic
induction medium. The appearance of endogenous lipid
droplets was observed by staining with Oil Red O after
2 weeks of culture (Figure 4C). For neurogenic differen-
tiation, the cells appeared to have the morphology of
neural-like cells after incubating with neurogenic
Figure 2 Proliferative ability curves and chromosomal stability. (A) The population doubling time pattern of a clonal AFS cell line
established by the starter cell method was investigated from primary culture at passage 0 to passage 20. The greatest proliferative ability of
hAFS cells was found at passage 0 and subsequently declined after trypsinization. (B) The average cumulative cell number of ten hAFS cell lines
derived by the starter cell method at the different days is shown in a growth curve. (C) The cumulative hAFS cell numbers derived from three
methods were compared. The green block is the cumulative number for the hAFS cell line, which was derived by the protocol described in [5].
The data for the yellow block was used from the report by Kim et al. in [4]. NR means no data reported. (D) A clonal AFS cell line at passage 18
was investigated for chromosomal stability after prolonged in vitro culture. The normal karyotype of a clonal AFS cell line is shown by Giemsa
staining.
Phermthai et al. BMC Cell Biology 2010, 11:79
http://www.biomedcentral.com/1471-2121/11/79
Page 5 of 9inducing medium and serum-depletion medium for 7
days. Finally, the cells showed positive staining for neu-
ron-specific class III b-tubulin (Figure 4C). The expres-
sion of Nestin was found in with RT-PCR product sizes
of 395 bp (Figure 3B).
Discussion
W eh a v ed e v e l o p e da ne f f i c i e n tm e t h o dt od e r i v eh A F S
cells for medical therapy. The requirements for stem
cells for use in clinical therapy include a pure stem cell
population, good cell quality, no animal product con-
tamination and rapid clonal hAFS cell production. Our
derivation technique was designed to meet these
requirements. The technique starts by selecting adherent
stem cells from a primary hAF culture. A selective indi-
vidual hAFS cells is called a “starter cell”.T h es t a r t e r
cell is used as a beginner cell for generating a clonal
hAFS cell line. In previous techniques, hAFS cell line
establishment utilizes primary hAF cell cultures, hAF
stem cell isolation and deriving a clonal line from a sin-
gle hAFS cell. With the starter cell method, these three
steps of AFS derivation protocol can be combined into a
single step. This makes the protocol simpler and
shorter. In addition, the obtained clonal AFS cell line
has high homogeneity. Thus, the starter cell method
creates high opportunity for providing hAFS cells that
fit for medical therapy.
For selection of the starter cells in a hAF primary cul-
ture, we utilized hAF cells which were actively prolifer-
ating. Based on the principles of cell division as
described in [7], dividing cells have increased cell mass
due to duplication of organelles, macromolecules and
Figure 3 Characteristics of hAFS cells obtained by the starter cell method. (A) Clonal hAFS cells at passage 18 show an Oct-4 specific
signal after staining with FITC-conjugated secondary antibody against anti-Oct4a with fluorescent microscope at 20× magnification. The Oct-4
positive signal is exhibit in hAFS population as shown by merge of Oct-4a and Hoechst 33342 staining. (B) The hAFS cell line at passage 18 has
expression of Oct-4a and HLA-ABC, but not HLA-DR, Nanog and Sox2 by cDNA analysis using RT-PCR. The expression of Nestin was observed in
hAFS cell-derived neurons. C means negative control, while gDNA was used as positive control of PCR amplification. (C) The flow cytometry
analysis shows expression of SSEA4, CD29, CD44, CD73, CD90, CD105 and CD133, but not CD34 or CD45 on the hAFS cell surface.
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some doubling and cell dividing in the G2 and M
phases. The coordination of cell division renders the
release of cell membrane stiffness, which leads to the
attachment of floating exfoliated AF cells on a culture
dish in the early days of culture.
The immunoselection method demonstrated in De
Coppi et al. [ 5 ]i sa ne f f i c i e n tt e c h n i q u eb yw h i c ht o
derive clonal hAFS cell lines from a heterogeneous cell
population. The hAFS cells derived by this technique
are suitable only for research study due to the use of
antibodies raised from animals. The antibodies contami-
nate the stem cell population, as they are of foreign ori-
gin. In order to make cells that are safe for human use,
our method was performed without xeno-immunologic
substances, allowing further technical developments for
a xeno-free production system.
The primary cells found in amniotic fluid are a het-
erogeneous population due to their varied origins. The
varied origins of the cells result in different degrees of
cell differentiation depending on the stage of organ
development. Only 1% of cells in amniotic fluid
Figure 4 Staining of hAFS cell-derived multi-lineage cells. A clonal hAFS cell line at passage 12 derived by the starter cell method was in
vitro induced with proper induction mediums and shows the appearance of lineage-specific signals of osteoblasts by staining with Alkaline
Phosphatase (A) and Von Kossa (B). The lineage-specific signals of adipocytes and neurons exhibit after staining with Oil Red O (C) and Tuj-1 (D),
respectively. 20× magnification was used.
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ods, the derivation protocol begins with routine amnio-
centesis and allowing the co-culturing of heterogeneous
hAF cells. We suspect that this step of amniocentesis
culture may unsuitable for hAFS cell derivation. The co-
culturing of heterogeneous hAF cells is similar to induc-
tion of differentiation using conditioned medium. The
conditioned medium is provided by the culturing of pri-
mary cells and then enriched with lineage-specific
growth factors. The conditioned medium can induce
stem cell differentiation via intracellular signaling path-
ways. Several differentiation studies have shown good
results by using this induction approach [8-11]. From
this, we understand that co-culturing of heterogeneous
hAF cells may affect the quality of the stem cells.
In the hAFS cell derivation method modified by Kim
et al. [4], the hAFS cells are co-cultured with AF pri-
mary cells for a long period of time. The population
doubling time of hAFS cells derived by this protocol
was shown to be 3.6 days. In contrast, the technique
developed by De Coppi et al. [5] cultures stem cells
with a heterogeneous population of primary AF cells for
a short period of time before immunoselection. These
hAFS cells showed a doubling time of 1.6 days.
Nevertheless, the starter cell method was designed to
avoid the culture of stem cells with a heterogeneous
population in primary culture. The obtained clonal
hAFS cell lines have a high proliferative ability and a 0.8
day population doubling time. This is 2-5 times faster
than the population doubling time with previous techni-
ques reported by De Coppi et al. [5] and Kim et al. [4].
The hAFS cells derived from our method show a steady
pattern of cell doubling over 20 subculture passages
with maintenance of a normal karyotype. They also
maintain the ability to differentiate and have stem cell
marker expression, including Oct-4, SSEA-4, CD29,
CD44, CD73, CD90, CD105, and CD133. These data
suggest a superior quality of the hAFS cells derived by
our method.
Each independent amniotic fluid sample contributes a
number of clonal hAFS cell lines using previous isola-
tion techniques. However, assessments of hAFS cell
lines have not been performed. Stem cell selection was
performed by random choosing of colonies, which often
results in inefficient cell lines. The selective line can also
be derived by repeated culture, which requires a higher
investment in money and time. Derivation of clonal
hAFS cell lines using the starter cell method can help to
eliminate the problem of random selection and the pre-
viously mentioned waste according to predict cell line
quality from outgrowth colony of each starter cell in pri-
mary culture. Furthermore, our method is a simple pro-
tocol that does not require a chemical kit, thus making
it more cost effective.
The hAFS cells found in our study are consistent with
t h o s ei d e n t i f i e db yT s a iet al. (2004) [1] and Kim et al.
(2007) [4], both of whom suggested that amniotic fluid
stem cells are morphologically a fibroblast cell type.
Conclusions
We report the starter cell method as a simple approach
to provide good quality hAFS cells that fit the require-
ments for use in therapeutic purposes. This technique
should allow the generation of fetal autogenic cell and
allogeneic support for future cell-based therapy. The
further step required for development of hAFS to clini-
cal level is elimination of xeno-component in hAFS cells
culture condition. Providing of xeno-free hAFS cells
should make the possibility and safety of hAFS cells for
medical therapy.
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